Matrix-assisted laser desorption/ionisation (MALDI) time-of-flight (TOF) mass spectrometry (MS) has proven to be an excellent technique for identification of illegally distributed peptides and proteins for human use. The identification of proteins is mainly based on peptide mass fingerprinting (PMF) – ie, the bottom-up approach – while the small proteins and peptides can be identified through the top-down approach. This paper reports on the application of MALDI for the identification of human growth hormone, melanotan II and delta sleep-inducing peptide…
Since 1992, with the coming of sensitive commercial instrumentation based on MALDI-TOF-MS, the technology has widely been used for protein and peptide identification.1,2 Since its development, MALDI-TOF-MS has been the primary instrumentation used for PMF,3,4 due to its high sensitivity and mass accuracy, speed, absence of multiple charge mass signals and relatively high tolerance toward additives and contaminants such as salts, matrix components and excipients.5 MALDI analysis requires only minimal sample treatment; ie, a few microlitres of sample and matrix are mixed and spotted on the MALDI target plate, which can also be automated. Furthermore, MALDI is a micro-destructive analytical technique and the remaining material on the MALDI target plate can be archived for later analysis. The high sensitivity of MALDI implies that only a small aliquot of a peptide or a protein digest is required, and the remainder can be used for alternative complementary measurements by other analytical techniques. Besides the accurate mass determination of peptides, MALDI provides additional information on the primary structure of the peptide by sequencing the peptide ions in post-source decay (PSD) mode.6 The predominant detection of singly charged peptide molecules by MALDI-MS facilitates the evaluation of PMFs significantly. In addition, MALDI provides sub-picomole limits of detection and a mass range in excess of 100kDa.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Figure 1: Schematic presentation of the protein/peptide identification by MALDI-TOF-MS. The sample being analysed is dissolved in 50mM ammonium bicarbonate (pH=7.5). One microlitre of the sample is then mixed with the matrix solution. The matrices being used for the analysis of native somatropin and the tryptic peptides have been sinapinic acid and a-cyano-4- hydroxycinnamic acid, respectively. Enzymatic degradation of analytes was performed by addition of trypsin into the analyte sample.
The concept of a proteolytic peptide pattern, ie, protein peptide mapping (PPM), being characteristic of a protein was first demonstrated by SDS-PAGE.7 In 1989, peptide sequencing by automated Edman degradation had a cycle time of nearly one hour per amino acid residue. Samples of interest often contained complex mixtures of proteins, which usually required separation by SDS-PAGE followed by electro blotting onto a PVDF membrane.8
However, a more rapid approach to protein identification is PMF. Using the bottom-up approach for PMF, the digested protein is analysed by MALDI-TOF-MS to generate mass-to-charge ratio (m/z) values in the mass spectrum, which in turn give rise to a characteristic ‘peptide mass fingerprint’ of the protein at nanogram level.9 The fingerprint serves to identify the protein through comparison with in silico digest of the corresponding reference standard.10 Trypsin is a commonly used proteolytic enzyme for PMF, since it is relatively cheap, highly selective and generates peptides with an average size of about 8–10 amino acids, which are ideally suited for analysis by MS. It cleaves principally on the C-terminal side of arginine (Arg) and lysine (Lys), with the exception of Arg-Pro and Lys-Pro.11 The drawback is that small peptides do not generate a peptide map that could be used for the identification. In such cases, the top-down approach is applied, ie, the intact peptide is subjected to PSD analysis in order to elucidate its amino acid sequence.
Figure 2: Peptide mass fingerprinting of human growth hormone, by MALDI-TOF-MS. The signature peptide characteristic for somatropin is marked in the spectrum. The photo below shows typical illegally distributed somatropin samples.
The singly-charged ions generated by MALDI-TOF-MS are a mixture of b-, y- and a-ions accompanied by ions resulting from neutral loss of ammonia or water.12 Protein identification, in the absence of a reference standard, is accomplished by using the PMF to search a protein sequence database by means of different search engines such as ProFound,13 MASCOT14 or SEQUEST.15 A value-based scoring system has been proposed that facilitates PMF-based protein identification without accompanying amino acid data.16 Those parameters considered to be important for the identification include: the isoelectric point (pI), molecular mass, protein sequence coverage and the number of matching proteolytic peptides.16 A scoring system has been developed where peptides are identified on the basis of identification points (IP).17 The molecular masses of both intact peptides and fragment ions are involved in the scoring system. The PMF-approach is based on bottom-up sequencing MS.10
Figure 3: MALDI-PSD spectrum from a tryptic fragment at m/z 930.5 in the somatropin peptide map
It has also been suggested that reliable identification of proteins upon proteolytic cleavage is possible by a minimal set of experimentally-derived peptide masses; ie, signature peptides termed a minimal protein identifier (MPI) generated by MALDI-MS.18 Prior reports19 suggest that a minimum of four matching peptides and a sequence coverage of at least 20 percent is necessary for positive PMF-based protein identification.20 However, a fingerprint comprised of only two peptides has demonstrated to be sufficient for identifying a protein.21
A broad range of proteins and peptides, for various purposes of enhancement, can be obtained from the illicit market. The scope of this article is to describe identification of human growth hormone (hGH, somatropin) and delta sleep-inducing peptide (DSIP) and melanotan II by MALDI-TOF-MS, as described in Figure 1.
Identification of recombinant human growth hormone
Figure 4: Amino acid sequencing of delta sleep-inducing peptide by MALDI-TOF-MS in PSD mode
Recombinant hGH, ie, somatropin, is a peptide hormone that consists of 191 amino acids with two disulfide bridges (Cys35–Cys165 and Cys182–Cys189) and promotes proteinogenesis and fat mobilisation and oxidation.22 Somatropin is a frequently occurring protein in illegally distributed samples seized by Swedish customs. Somatropin is identified through PMF (Figure 2).23
The spectrum from unalkylated tryptic somatropin, in Figure 2, contained a unique mass signal at m/z 1400.59, which originated from one fragment ion consisting of two tryptic peptides (ie, IVQCR and SVEGSCGF), being bound to each other through a disulphide bridge. This Cys (at position182)-Cys (at position189) cross-linked peptide fragment is used as a signature peptide for the identification. It is possible to select one or more peptides in the map to perform PSD analysis in order to confirm their amino acid sequences. As an example, Figure 3 demonstrates the PSD analysis of one of the tryptic peptides, ie, FPTLPEISR.
Mass signals originating from incomplete digestion fragments enhanced sequence coverage from 75 to 79 percent. A tryptic peptide containing oxidised methionine at site 170, ie, DMoxDKVETFLR, was also detected.
Identification of delta sleep-inducing peptide
Figure 5: Identification of melanotan II by MALDI‑TOF-MS in PSD mode
The DSIP (WAGGDASGE; M [mono-isotopic] = 848.34 Da) was primarily believed to be involved in sleep regulation due to its apparent ability to induce slow-wave sleep in rabbits. However, it has been demonstrated that short-term treatment of chronic insomnia with DSIP is likely not of major therapeutic benefit.24 The peptide is marketed illegally, presumably for the treatment of insomnia, and is identified through the top-down approach by being directly exposed to the PSD analysis. The results summarised in Figure 4 confirmed the molecular mass as well as the primary structure of the peptide.
Identification of melanotan II
Melanotan II (Figure 5) is a cyclic peptide, which induces melanogensis (ie, tanning of the skin) by activation of the MC1 receptor, being an analogue to alfa melanocyte hormone (α-MSH).25 Melanotan activity on other receptors, ie, MC3 and MC4 receptors in the spinal cord and central nervous system, results in sexual arousal.25 However, injection of melanotan II can result in systemic toxicity and rhabdomyolysis.25 Similarly to DSIP, this peptide is also identified through the top-down approach by MALDI in PSD mode (Figure 5). It is to be noted that this polypeptide did not generate a useful MS-MS spectrum when analysed by LC-MS.26
Conclusions
The quality and safety of illegally distributed products, with respect to the purity and endotoxin level as well as the microbiological quality, may present a serious health threat to the users and to public health. MALDI-TOF-MS provides an efficient procedure for the identification of peptides and proteins in illegally distributed samples. The use of trypsin as a proteolytic enzyme generated peptide fragments covering 40 to 80 percent of the amino acid sequence of the analysed human growth hormone. The presence of a signature peptide in the peptide map expedited analyte identification considerably. MALDI-TOF-MS was also applied in the PSD mode for the amino acid sequencing of selected tryptic peptides as well as small peptides.
Author Biographies
TORGNY RUNDLÖF is a pharmaceutical evaluator at the Swedish MPA. He received his PhD in organic chemistry in 1998 at Stockholm University. The study, which was carried out with Professor Göran Widmalm, focused on NMR studies of the structure and dynamics of carbohydrates. In 2000 he joined the MPA as an NMR specialist. His recent work deals with supervision of various registered medicinal products, using spectroscopy techniques such as NMR, IR and MS, some of which has been published. Currently, he examines the potential of NMR and MS for characterisation of biopharmaceuticals including illegally distributed products.
AHMAD AMINI is a pharmaceutical assessor at the Swedish MPA. He received his PhD in analytical pharmaceutical chemistry in 1998 at Uppsala University. The thesis work, which involved enantiomeric separation of pharmaceutical compounds using CE, was carried out under supervision of Professor Douglas Westerlund and Associate Professor Curt Pettersson. Following post-doctoral studies on proteomics at Purdue University, West Lafayette, US, under supervision of Professor Fred E. Regnier he joined the MPA laboratory in 2001. Currently, he is involved in method development for the European Pharmacopoeia and MS characterisation of biopharmaceuticals including illegally distributed products.
HENRIK LODÉN is a pharmaceutical evaluator at the Swedish MPA. He received his PhD in analytical pharmaceutical chemistry in 2008 at Uppsala University. The thesis work, which involved separation of pharmaceutical compounds using different modes of CE, was carried out under supervision of Professor Curt Pettersson, Associate Professor Torbjörn Arvidsson and Associate Professor Ahmad Amini. Following employments in the pharmaceutical industry and as a researcher in academia, using MALDI and LC-MS, he joined the MPA laboratory in 2015. Currently, he is involved in method development for the European Pharmacopoeia and MALDI identification of illegally distributed biopharmaceutical products.
References
1. Karas M, Hillenkamp F. Anal Chem 1988, 60, 2299–3201.
2. Pappin DJC, Hojrup P, Bleasby AJ. Current Biol 1993, 3, 327–332.
3. Gevaert K, Vandekerckhove J. Electrophoresis 2000, 21, 1145–1154.
4. Pandey A, Mann M. Nature 2000, 405, 837–846.
5. Amini A, Dormady SJ, Riggs L, Regnier FE. J Chromatogr A 2000, 894, 345–355.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Well written and to the point. I appreciate the detail in this article!